What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
Syapse
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
Syapse Leverages Machine Data Analytics to Safeguard Global Patient Data
- Today, Syapse and Sumo Logic have released an announcement furthering the support and delivery of valuable real-world data-based insights to its health system and life sciences partners. - Sumo Logic’s standardized process, security and audit capabilities are helping Syapse through a global health system network, adhere to strict healthcare data regulations.Sumo Logic, the leader in continuous intelligence, today announced that Syapse has chosen Sumo Logic to support the delivery of valuable
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry.
- The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients.
- A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.Methods to Derive RWE From Multiple
Read More
SHUH, Syapse to Build South Korea’s First Real-World Data Sharing Network for Precision Oncology Hospitals
SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More
Pfizer, Syapse Partner on Oncology Precision Medicine Using Real-World Evidence (RWE)
Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.Syapse NetworkThe Syapse Network enables health systems and their providers to learn
Read More
Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More
Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care
New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care. The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. For Syapse, the data contained in theNCCN Biomarkers Compendium will
Read More
Syapse Precision Medicine Council Launches to Advance Precision Oncology Adoption
Syapse, a San Francisco, CA-based precision medicine company, announced today the formation of the Syapse Precision Medicine Council, a group of oncology, operations, and research leaders from health systems dedicated to advancing precision oncology adoption through sharing best practices.Inaugural members include Henry Ford Health System, Catholic Health Initiatives and Dignity Health (the Precision Medicine Alliance), Providence St. Joseph Health, Aurora Health Care, and the University of
Read More
